Oncology Brothers: Practice-Changing Cancer Discussions

In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center.
 
We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and the importance of bridging and holding therapies.
 
Key topics covered in this episode:
Frontline treatment options for DLBCL
The role of polatuzumab in early-stage disease
Treatment paradigms for advanced-stage DLBCL
CAR T-cell therapy: who should receive it and when
The importance of community and tertiary care partnerships in improving patient access to innovative therapies
 
Join us for an informative discussion that highlights the evolving landscape of DLBCL treatment and the critical role of collaboration in oncology care.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and share your thoughts in the comments!
#DLBCL, #CARTtherapy, #RCHOP, #Polatuzumab, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dove deep into the groundbreaking advancements in pancreatic cancer treatment, focusing on the recent approval of daraxonrasib.
 
Join us as we welcome Mark Goldsmith, MD, PhD, CEO of Revolution Medicines, who shared his inspiring journey from clinical practice to the biotech industry. Discover the challenges and triumphs behind bringing this first-in-class drug to market, and learn about the significant impact it has on patient outcomes.
 
Keypoints:
Daraxonrasib is a first-in-class RAS inhibitor approved for the treatment of pancreatic cancer, targeting a mutation present in over 90% of cases.
The drug's development represents a major shift in pancreatic cancer, moving from a historically untreatable disease to a promising target for precision medicine.
Early clinical trial results demonstrated remarkable tumor shrinkage, driving urgency to bring the therapy to patients.
Management of side effects, including rash and gastrointestinal issues, is essential for optimal patient outcomes.
Ensuring patient access—despite high treatment costs—remains a priority, with patient assistance programs and insurance navigation support in place.
Future directions include combination therapies and the goal of transforming pancreatic cancer into a manageable chronic disease.
 
We discussed the critical gaps between academic research and community practice, the importance of understanding side effects, and the financial implications of new therapies. Dr. Goldsmith also highlighted the future of pancreatic cancer treatment and the ongoing commitment to improving patient care.
 
Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights and information.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in cancer treatment and research!
#PancreaticCancer, #Daraxonrasib, #RASinhibitor, #DrugDevelopment, #OncologyBrothers

Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial.
We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana-Farber Cancer Institute, who shared her insights on the trial's design, findings, and the significance of detecting ESR1 mutations before clinical progression. We discussed the implications of this approval, including the shift in treatment strategies, the importance of ctDNA monitoring, and the potential benefits for patient quality of life.
Key topics covered in this episode:
Overview of the SERENA-6 trial and its findings
The role of ESR1 mutations in treatment resistance
The efficacy and safety profile of camizestrant
Practical insights on integrating next-generation sequencing (NGS) testing into clinical practice
Management of side effects, including bradycardia and QT prolongation
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#Camizestrant, #SERENA6, #ESR1mutation, #BreastCancer, #OncologyBrothers
 

Welcome to the Oncology Brothers podcast! In this episode, we talked about the most recent developments in the world of myeloproliferative neoplasms (MPNs), including the exciting FDA approvals of ropeginterferon alfa-2b for essential thrombocythemia (ET) and rusfertide for polycythemia vera (PV).
 
The leading author Dr. John Mascarenhas, an MPN specialist from the Mount Sinai, New York, shared insights from the SURPASS-ET study, which paved the way for the official approval of ropeginterferon alfa-2b in ET. Dr. Mascarenhas discussed the study design, findings, and the implications of using ropeginterferon alfa-2b compared to traditional therapies like anagrelide and hydroxyurea.
 
Key topics covered in this episode included:
Overview of the SURPASS-ET study and its significance
Efficacy and tolerability of ropeginterferon alfa-2b in ET
Side effect profiles of ropeginterferon alfa-2b vs anagrelide
The importance of monitoring JAK2 allele burden and its clinical relevance
Considerations for using ropeginterferon alfa-2b in frontline therapy for select patients
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Join us as we explore the evolving landscape of MPN treatment and the potential for disease modification with ropeginterferon alfa-2b. Don't forget to like, subscribe, and check out our other discussions on oncology topics!
#EssentialThrombocythemia, #MPN, #Ropeginterferon, #SURPASSET, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute.
 
Join us as we explored:
The critical distinction between primary and secondary myelofibrosis and its implications for treatment
The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis
Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept
The role of JAK inhibitors in treatment, including ruxolitinib, momelotinib, pacritinib, and fedratinib, and how to choose among them based on patient needs
The importance of spleen reduction and its correlation with patient outcomes and survival
Insights into the side effect profiles of various treatments and the future of myelofibrosis management
 
Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! 
#Myelofibrosis, #JAKinhibitors, #Hematology, #MPN, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET).
 
We dived deep into the side effect profiles and management strategies for key treatments, including:
Hydroxyurea: Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks
Ropeginterferon alfa-2b: Discover the benefits and potential side effects, including flu-like symptoms and neuropsychiatric issues, and how to approach dosing for patients with pre-existing conditions
Ruxolitinib: Understand the common side effects, including myelosuppression and weight gain, and the critical importance of tapering off the medication rather than stopping abruptly
Rusfertide: Get insights into this new hepcidin mimetic and its promising role in managing PV, along with potential side effects to monitor
 
Join us for a comprehensive tox check discussion that aims to equip healthcare professionals with clinical pearls for managing these treatments effectively.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
X/Twitter: ⁠https://x.com/oncbrothers⁠ 
⁠Instagram: ⁠https://www.instagram.com/oncbrothers⁠ 
Website: ⁠https://oncbrothers.com/⁠ 
 
Subscribe for more insights and updates from the Oncology Brothers!
#PolycythemiaVera, #MPN, #EssentialThrombocythemia, #CytotoxicTherapies, #OncologyBrothers
 

Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications.
 
Key topics discussed included:
The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron deficiency
The design and findings of the VERIFY study, highlighting the significant reduction in the need for phlebotomy among patients treated with rusfertide
The potential for individualized patient care and the integration of rusfertide with existing cytoreductive therapies
Insights into dosing, side effects, and the drug's impact on patient quality of life
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Join us as we explore how rusfertide can change the treatment landscape for polycythemia vera and improve patient outcomes. Don't forget to like, subscribe, and hit the notification bell for more episodes!
#Rusfertide, #PolycythemiaVera, #VERIFYstudy, #MPN, #Hematology

Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polycythemia vera (PV) and essential thrombocythemia (ET).
 
Join us as we delved into:
The diagnostic criteria for PV and ET, including the significance of JAK2 mutations and erythropoietin (EPO) levels
The role of bone marrow biopsies in diagnosing and managing these conditions
Treatment options for PV, including hydroxyurea, ropeginterferon alfa-2b, and ruxolitinib, as well as the approval of rusfertide
The importance of risk stratification based on patient age and history of thrombosis
The management of side effects associated with various treatment options
The clinical utility of monitoring JAK2 allele burden and its implications for patient management
Insights into the treatment landscape for ET, including the use of antiplatelet therapy and the role of acquired Von Willebrand disease
 
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of managing PV and ET.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in hematological and oncological care!
#PolycythemiaVera, #EssentialThrombocythemia, #MPN, #JAK2, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode of our Partners in Practice series, we dived into the world of multiple myeloma treatment. We had the opportunity to engage with the dedicated team from UCSF, including Dr. Ajai Chari, a myeloma specialist, nurse practitioner Samantha Shenoy, NP, and clinical nurse Jenny Truong, RN.
 
In this insightful discussion, we covered:
The current standard of care for newly diagnosed multiple myeloma patients, focusing on quadruple therapy
The role of anti-CD38 therapies like daratumumab and isatuximab in treatment regimens
Patient expectations regarding side effects and the importance of supportive care
The dynamics of teamwork in oncology, emphasizing communication and collaboration among healthcare professionals
 
Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer care, this episode offers valuable insights into the complexities of treating multiple myeloma.
 
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!
#MultipleMyeloma, #QuadTherapy, #Daratumumab, #Isatuximab, #OncologyBrothers

We had a chance to dive into one of the most significant advancements in the treatment of HER2-positive gastroesophageal junction (GEJ) and gastric adenocarcinoma. In this episode, we discussed the groundbreaking HERIZON-GEA-01 study that led to the approval of zanidatamab, a novel bispecific HER2-directed antibody.
 
We welcomed Dr. Nataliya Uboha, a GI medical oncologist from the University of Wisconsin, who shared her insights on the study's design, findings, and the implications for clinical practice. Learn about the importance of biomarker testing, the mechanism of action of zanidatamab, and how it compares to traditional therapies like trastuzumab.
 
Key topics covered in this episode:
Overview of the HERIZON-GEA-01 study and its findings
Mechanism of action of zanidatamab
Comparison of treatment regimens and overall survival benefits
Management of side effects, including diarrhea and infusion reactions
The role of PD-L1 testing in treatment decisions
 
Whether you're a healthcare professional or simply interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of treatment for HER2-positive upper GI malignancies.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and check out our other discussions on FDA approvals, treatment algorithms, and challenging cases!
 
#GastricCancer, #HER2positive, #Zanidatamab, #HERIZONGEA01, #OncologyBrothers